New Study: Study of Ibrutinib Resistance Development and Intervention with Venetoclax in CLL

[Jm954]

The Ohio state University, Columbus

This phase 2 study is designed to follow CLL pts taking Ibrutinib and at high risk for resistance (observation cohort) and to test venentoclax in combination with Ibrutinib for those who develop Progressive Disease (intervention cohort).

This will determine: the incidence of Ibrutinib Resistance Mutations (IRmut) and Progressive Disease (PD) in this population, the ORR with Ibrutinib/Venetoclax, and the ability of this combination to eliminate IRmutations.

This multicenter phase 2 trial examines the development of IRmut and clinical resistance to ibr in a cohort of high-risk CLL pts and will determine the efficacy of adding ven to ibr in those who develop PD.

More details here: ash.confex.com/ash/2019/web...

Jackie

[Yvbb]

Thank you, Jackie!

[cartwheels]

Sounds promising thanks Jackie 🙌

[Smakwater]

So much good information lately. I cannot keep up with the reading and I feel like I am having finals anxiety.

Waking up in the middle of the night with memorization nightmares. Term paper is a linear program with a CLL cure matrix calculation displayed in a power point presentation.

Got go now, this is due in the morning!

Please don't wake me,

JM